foxo4 dri human trials results FOXO4-DRI PEPTIDE 2MG/5MG/10MG VIAL – UMBRELLA Labs The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



